Marinus Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is February - January.

Millions CAD. Fiscal year is Feb - Jan.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '25 Apr 30, 2025	Jan '25 Jan 31, 2025	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022	Jan '21 Jan 31, 2021
Revenue	0.27	0.37	0.35	0.78	0.36	-
Revenue Growth (YoY)	-37.97%	4.87%	-55.08%	113.25%	-	-
Cost of Revenue	0.25	0.3	0.26	0.52	0.43	-
Gross Profit	0.02	0.06	0.09	0.25	-0.07	-
Selling, General & Admin	0.45	0.47	0.98	1.28	2.66	0.25
Research & Development	0.25	0.34	0.35	0.41	0.41	0.54
Operating Expenses	0.71	0.81	1.33	1.69	3.08	0.8
Operating Income	-0.68	-0.75	-1.24	-1.43	-3.14	-0.8
Interest Expense	-0	-0	-0.02	-0	-0	-
Currency Exchange Gain (Loss)	0	-0	-0	-0	-0.02	-0
Other Non Operating Income (Expenses)	-0.04	-0.05	-0.08	-0.03	-0.07	-0
EBT Excluding Unusual Items	-0.72	-0.81	-1.34	-1.47	-3.23	-0.8
Other Unusual Items	-	-	0.01	-	-8.02	-
Pretax Income	-0.72	-0.81	-1.32	-1.47	-11.25	-0.8
Net Income	-0.72	-0.81	-1.32	-1.47	-11.25	-0.8
Net Income to Common	-0.72	-0.81	-1.32	-1.47	-11.25	-0.8
Shares Outstanding (Basic)	33	33	31	28	25	15
Shares Outstanding (Diluted)	33	33	31	28	25	15
Shares Change (YoY)	3.37%	6.75%	12.21%	10.16%	63.41%	-
EPS (Basic)	-0.02	-0.02	-0.04	-0.05	-0.45	-0.05
EPS (Diluted)	-0.02	-0.02	-0.04	-0.05	-0.45	-0.05
Gross Margin	9.16%	17.49%	25.98%	32.71%	-17.90%	-
Operating Margin	-251.59%	-205.16%	-354.84%	-185.03%	-863.86%	-
Profit Margin	-266.97%	-220.87%	-379.79%	-189.72%	-3094.56%	-
EBITDA	-	-	-	-	-3.14	-
D&A For EBITDA	-	-	-	-	0.01	-
EBIT	-0.68	-0.75	-1.24	-1.43	-3.14	-0.8
EBIT Margin	-251.59%	-205.15%	-	-185.03%	-	-

Updated Dec 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.